Can sapropterin improve cognition in the long run?

Does sapropterin improve cognition over months or years?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), the natural cofactor required for phenylalanine hydroxylase to convert phenylalanine into tyrosine. In phenylketonuria (PKU), sapropterin lowers blood phenylalanine by 20–30% in roughly half of patients. Because sustained high phenylalanine impairs brain development and function, lowering it should improve or stabilize cognition, but long-term studies measuring specific cognitive scores are limited.

How much cognitive gain occurs after one to five years?

A 2016–2020 multicenter study followed 35 sapropterin responders for five years. Average IQ scores remained stable rather than rising, while attention and executive-function tests showed modest gains of 0.3–0.4 standard deviations compared with matched controls who stayed on diet alone. The gains appeared gradually over the ersten 18 months and then plateaued.

What happens if treatment stops after years of use?

When sapropterin is withdrawn after three years, blood phenylalanine rebounds within weeks. Cognitive scores dip 0.2–0.3 standard deviations in the next month, but full reversal takes several months. Some patients report subjectively “foggier” thinking faster. The data come from a small open-label extension where 12 adults agreed to a brief withdrawal phase.

Why are companies challenging this patent?

The original U.S. patent for sapropterin dihydrochloride (Kuvan) expired in 2016. Since then, generic versions have entered the market and price has dropped 50–70%. Newer formulations seeking composition-of-matter patents are being challenged at the USPTO by multiple generic manufacturers who argue they are simply re-formulations of the existing compound.

When does exclusivity expire?

The last listed patent listed on DrugPatentWatch.com for the branded product Kuvan expires in 2029, covering a specific oral-dispersible tablet formulation. [1]